Clinical Trial Results:
            A phase III randomised, double-blind, placebo-controlled, parallel group, efficacy and safety study of linagliptin (5 mg), administered orally once daily over 24 weeks in type 2 diabetic patients (age ≥ 70 years) with insufficient glycaemic control (HbA1c ≥ 7.0) despite metformin and/or sulphonylurea and/or insulin therapy
    
|     Summary | |
|     EudraCT number | 2009-015255-25 | 
|     Trial protocol | NL DK SE | 
|     Global completion date | 
                                    22 Jun 2011
                             | 
|     Paediatric regulatory details | |
|     Is the trial part of an agreed EMA paediatric investigation plan? | 
                                        No
                                 | 
|     Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? | 
                                        No
                                 | 
|     Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? | 
                                        No
                                 | 
|     Results information | |
|     Results version number | v1(current) | 
|     This version publication date | 
                                    16 May 2016
                             | 
|     First version publication date | 
                                    05 Apr 2015
                             | 
|     Other versions | |
|     Summary report(s) | 1218.63 | 
            Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to            Commission Guideline 2012/C 302/03
            for further information.    
 
				
